Trending NewsTrending NewsNASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis $45.04 +6.17 (+15.87%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$45.40 +0.36 (+0.80%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Edgewise Therapeutics Stock (NASDAQ:EWTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edgewise Therapeutics alerts:Sign Up Key Stats Today's Range$38.04▼$45.7650-Day Range$36.28▼$46.9452-Week Range$16.70▼$48.51Volume3.71 million shsAverage Volume1.35 million shsMarket Capitalization$4.89 billionP/E Ratio5.50Dividend YieldN/APrice Target$52.83Consensus RatingModerate Buy Company Overview Edgewise Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited. Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy. The company is evaluating sevasemten in clinical studies involving patients with these disorders and other potential muscle-related conditions. The company is also developing EDG-7500, an investigational cardiac sarcomere modulator being studied for potential use in hypertrophic cardiomyopathy. Edgewise was founded in 2017 and is headquartered in Boulder, Colorado. Its programs are being advanced through clinical development intended to support potential treatment applications in patients in the United States and other international markets. Kevin Koch, Ph.D., serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Edgewise Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreEWTX MarketRank™: 3.24722748174 of 5 starsEdgewise Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 135th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEdgewise Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialEdgewise Therapeutics has a consensus price target of $52.83, representing about 17.3% upside from its current price of $45.04.Amount of Analyst CoverageEdgewise Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edgewise Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Edgewise Therapeutics are expected to grow in the coming year, from ($2.09) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is 5.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is 5.50, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.54.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 9.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.75% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 8.48.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 4.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.60 News SentimentEdgewise Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Edgewise Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for EWTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,675,529.00 in company stock.Percentage Held by Insiders21.30% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsEdgewise Therapeutics has minimal institutional ownership at this time.Read more about Edgewise Therapeutics' insider trading history. Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EWTX Stock News HeadlinesEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up on Better-Than-Expected EarningsNovember 7 at 2:18 AM | americanbankingnews.comStock Traders Buy Large Volume of Edgewise Therapeutics Put Options (NASDAQ:EWTX)November 7 at 1:20 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.November 7 at 1:00 AM | Porter & Company (Ad)Edgewise Therapeutics gains amid report of takeover interestNovember 6 at 4:28 PM | msn.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Target Lowered at WedbushNovember 6 at 4:12 AM | americanbankingnews.comEdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo ...November 5 at 3:20 PM | finance.yahoo.comEdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo MonitoringNovember 5 at 8:00 AM | prnewswire.comEdgewise Therapeutics Reports Third Quarter 2026 Financial ResultsNovember 4 at 4:01 PM | prnewswire.comSee More Headlines EWTX Stock Analysis - Frequently Asked Questions How have EWTX shares performed this year? Edgewise Therapeutics' stock was trading at $24.82 at the beginning of 2026. Since then, EWTX shares have increased by 81.5% and is now trading at $45.04. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its quarterly earnings results on Wednesday, November, 4th. The company reported $9.65 EPS for the quarter, topping the consensus estimate of ($0.53) by $10.18. When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $165 million in an IPO on Friday, March 26th 2021. The company issued 11,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.68%), Pictet Asset Management Holding SA (0.61%), Aberdeen Group plc (0.38%) and Russell Investments Group Ltd. (0.23%). Insiders that own company stock include Orbimed Advisors Llc, Peter A Thompson, R Michael Carruthers, Kevin Koch, Alan J Russell, Jonathan C Fox, Badreddin Edris, John R Moore, Behrad Derakhshan, Joanne M Donovan and Marc Semigran. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edgewise Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edgewise Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Oracle (ORCL), Taiwan Semiconductor Manufacturing (TSM), Micron Technology (MU), AST SpaceMobile (ASTS) and Cytokinetics (CYTK). Company Calendar Last Earnings11/04/2026Today11/07/20263rd Annual Guggenheim Healthcare Innovation Conference11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 EWTX's financial health is in the Green zone, according to TradeSmith. EWTX has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EWTX CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees127Year Founded1962Price Target and Rating Average Price Target for Edgewise Therapeutics$52.83 High Price Target$85.00 Low Price Target$25.00 Potential Upside/Downside+17.3%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$8.19 Trailing P/E Ratio5.50 Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-39.01% Return on Assets-36.96% Debt Debt-to-Equity RatioN/A Current Ratio16.24 Quick Ratio16.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book9.14Miscellaneous Outstanding Shares108,600,000Free Float85,471,000Market Cap$4.89 billion OptionableOptionable Beta0.39 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:EWTX) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredDr. Ron Paul: “This is even worse than the big Socialist victory”Democratic Socialists tripled their seats in Congress this election cycle and claimed the D.C. mayor's office....Stansberry Research | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredOne Ticker Tied to a Coming 401k ChangeAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredTesla pays $0 in dividends. This new fund paid $452 in one month on $5,000.Tesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a differen...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
